Loading company…
Zion Pharma Limited of Shanghai develops small molecule tumor drugs, led by ZN-A-1041, a HER2 tyrosine kinase inhibitor.
Based in Shanghai, China and established in 2018, Zion Pharma Limited develops small molecule tumor drugs. Its main product, ZN-A-1041, is a tyrosine kinase receptor inhibitor targeting HER2, used for HER2 and advanced breast cancer brain metastases. The company has also built a new drug discovery platform. Co-founder and CEO Dr. Ziqiang Cheng previously served as Director of Drug Metabolic Pharmacokinetics at AstraZeneca and GlaxoSmithKline. It is listed at Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in